Business
PDMR Dealing/Grant of Share Options
PDMR Dealing/Grant of Share Options.
About this update from Oxford Biodynamics Plc
[{"type":"text","content":"\n \nRNS Number : 0700I Oxford BioDynamics PLC 19 March 2018 \n\nOXFORD BIODYNAMICS PLC\n \nPDMR DEALING/GRANT OF SHARE OPTIONS\n \n \nLondon, 19 March 2018: Oxford BioDynamics Plc (AIM: OBD) (the \"Company\"), a biotechnology company focused on the discovery and development of epigenetic biomarkers based on regulatory genome architecture for use within the pharmaceutical and biotechnology industry, announces that it has today granted 160,000 options over its ordinary shares of 1 pence each to certain employees, including 120,000 options to Paul Stockdale, Chief Financial Officer and a Director of the Company. The options were granted under the Company's 2016 Employee Option Plan, with an exercise price of 170 pence per share.\n \nOne-third of the options granted will vest and become exercisable on the first anniversary of the grant date; one-third on the second anniversary and one-third on the third anniversary. Vested options will remain exercisable up to and including the tenth anniversary of the date of grant.\n \nFollowing this grant, Paul Stockdale holds 120,000 options and the notification below, which is made in accordance with the requirements of the EU Market Abuse Regulation, provides further details.\n \nFor further details, contact:\n \n\n\n\n\n\n\n\n \n\n\n\n\nOxford BioDynamics Plc\n\n\n+44 (0)1865 518910\n\n\n\n\nChristian Hoyer Millar, CEO\n\n\n\n\n\n\n\nPaul Stockdale, CFO\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nShore Capital\n\n\n+44 (0)20 7408 4090\n\n\n\n\nBroker and Nominated Adviser\n\n\n\n\n\n\n\nStephane Auton\nEdward Mansfield\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nFTI Consulting\n\n\n+44 (0)20 3727 1000\n\n\n\n\nFinancial Public Relations Adviser\n\n\n\n\n\n\n\nBrett Pollard\n\n\n\n\n\n\n\nNatalie Garland-Collins\n\n\n\n\n\n\n\n \nNotes for Editors\n \nAbout Oxford BioDynamics Plc\n \nOxford BioDynamics Plc (AIM: OBD) (\"Oxford BioDynamics\") is a biotechnology company focused on the discovery and development of epigenetic biomarkers for use within the pharmaceutical and biotechnology industry.\n \nThe Company's award-winning, proprietary technology platform, EpiSwitch™, aims to accelerate the drug discovery and development process, improve the success rate of therapeutic product development and take advantage of the increasing importance of personalised...